Amyloid imaging to prevent Alzheimer’s disease (AMYPAD)

The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) is a European collaboration between the academic and private sector to improve knowledge, diagnosis and treatment of Alzheimer’s via the use of Positron Emission Tomography (PET) brain scanners. The project consists of three sub-studies. The first is focused on determining the value of this test in diagnosis and clinical management of people in a spectrum that goes from subjective memory complaints to mild cognitive disorder and atypical dementia. The second will be carried out to improve understanding of the natural history of the illness, in coordination with the EPAD (European Prevention of Alzheimer’s Dementia) project longitudinal cohort study. Finally, evaluation models of the illness will be constructed to calculate inclusion criteria in clinical trials and to monitor efficacy of new individualized treatment.

As well as providing participants for the study, the Barcelonaβeta Brain Research Center will work on the methodology and logistics design.

The project is financed with grant number 115952 of program 2 of the Innovative Medicines Initiative, which is a joint initiative of the research and innovation program of the European Commission Horizon 2020, and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Juan Domingo Gispert
AMYPAD allows us to establish the amyloid PET value both for clinical management of patients with signs that lead us to believe they may have Alzheimer’s, as well as determining the efficacy of new investigational drugs with the aim of eliminating clusters of cerebral amyloid

Juan Domingo Gispert

Neuroimaging Unit Manager

For a future without Alzheimer’s disease

Your donation will be used for scientific research to beat the disease.